1-20 of 22
Keywords: Bortezomib
Close
Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2020) 143 (2): 146–154.
Published Online: 21 August 2019
... setting, the combination of intravenous bortezomib and oral vorinostat (BV) was studied and showed efficacy. Therefore, it was reasonable to study this combination therapy post-ASCT. Patients and Methods: We report on BV given post-ASCT. All 30 patients underwent conditioning for ASCT with high-dose...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2019) 141 (2): 111–118.
Published Online: 06 February 2019
...; Junichi Mukae; Koh Yamamoto; Ikuyo Tsutsumi; Takuya Komeno; Chikashi Yoshida; Masahide Yamamoto; Hiroshi Kojima; on behalf of the Ochanomizu Hematology Study Group We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2016) 136 (3): 140–146.
Published Online: 14 July 2016
... was conducted that included 68 patients treated in the last 10 years, 37 of whom received bortezomib only (bortezomib group), 13 of whom received bortezomib and underwent autologous hematopoietic stem cell transplantation (bortezomib + ASCT group), and 18 of whom received conditional chemotherapy (non...
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2015) 134 (1): 25–31.
Published Online: 03 April 2015
... Party (IB-HOPE) Aims: To explore the biomarker for predicting the occurrence of adverse events in myeloma patients treated by intravenous bortezomib, we measured proteasome activity in peripheral blood mononuclear cells. Methods: Samples were obtained from 34 bortezomib-naïve patients. Proteasome...
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2014) 132 (2): 211–219.
Published Online: 22 March 2014
... and the European Myeloma Network Novel agents such as thalidomide, lenalidomide and bortezomib have dramatically changed the treatment paradigm of multiple myeloma (MM). However, it is not clear whether these agents improve the prognosis of elderly patients who have undergone autologous stem cell transplantation...
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2013) 129 (4): 207–214.
Published Online: 15 May 2013
... are urgently needed. Bortezomib (Velcade, formerly PS-341) is the first proteasome inhibitor approved by the US FDA for the treatment of newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma and mantle cell lymphoma. Although the mechanisms of bortezomib anticancer activity are still...
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Journal Articles
Subject Area:
Hematology , Oncology
Acta Haematol (2007) 117 (4): 211–214.
Published Online: 18 January 2007
...Sung-Jin Moon; Chang-Ki Min; Dong-Gun Lee; Seok Lee; Jong-Wook Lee; Woo-Sung Min; Chun-Choo Kim; Myungshin Kim; Gyeongsin Park; Younggu Kim The proteasome inhibitor, bortezomib, has antimyeloma activity even in myeloma cells refractory to multiple prior treatments. The most commonly reported...